Clinical relevance of androgen receptor alterations in prostate cancer. Issue 8 (November 2017)

• Record Type: Journal Article
• Authors: Jernberg, Emma; Bergh, Anders; Wikström, Pernilla
• Is Part Of: Endocrine connections. Volume 6:Issue 8(2017)
• Page Start: R146
• Page End: R161
• Publication Date: 2017-11
• Subjects: prostate cancer -- castration resistance -- androgen receptor; Endocrinology -- Periodicals; 616.4005
• DOI: 10.1530/EC-17-0118
• Languages: English
• ISSNs: 2049-3614

Abstract

Abstract : Prostate cancer (PC) remains a leading cause of cancer-related deaths among men worldwide, despite continuously improved treatment strategies. Patients with metastatic disease are treated by androgen deprivation therapy (ADT) that with time results in the development of castration-resistant prostate cancer (CRPC) usually established as metastases within bone tissue. The androgen receptor (AR) transcription factor is the main driver of CRPC development and of acquired resistance to drugs given for treatment of CRPC, while a minority of patients have CRPC that is non-AR driven. Molecular mechanisms behind epithelial AR reactivation in CRPC include AR gene amplification and overexpression, AR mutations, expression of constitutively active AR variants, intra-tumoural and adrenal androgen synthesis and promiscuous AR activation by other factors. This review will summarize AR alterations of clinical relevance for patients with CRPC, with focus on constitutively active AR variants, their possible association with AR amplification and structural rearrangements as well as their ability to predict patient resistance to AR targeting drugs. The review will also discuss AR signalling in the tumour microenvironment and its possible relevance for metastatic growth and therapy.